Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Zalicus Inc. (ZLCS)

1.21 Down 0.14(10.37%) Apr 17, 3:59PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Zalicus Inc.
245 First Street
Third Floor
Cambridge, MA 02142
United States - Map
Phone: 617-301-7000
Fax: 617-301-7010

Index Membership:N/A
Full Time Employees:27

Business Summary 

Zalicus Inc., a biopharmaceutical company, discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company has collaboration agreements with Mallinckrodt Inc.; Fovea Pharmaceuticals SA; Institutes of BioMedical Research, Inc.; Amgen Inc.; and United States Army Medical Research Institute. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. in September 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Zalicus Inc.

Key Executives 
Dr. Mark H. N. Corrigan M.D., 56
Chief Exec. Officer, Pres and Director
Mr. Justin A. Renz , 42
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Treasurer
Dr. Terrance P. Snutch Ph.D., FRSC, DSc (hon),
Chief Scientific Officer and Sr. VP
Ms. Gina Nugent ,
VP of Corp. Communications and Investor Relations
Dr. C. Eugene Wright PharM.D., Ph.D.,
Chief Devel. Officer and Sr. VP
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders